Drug Trial Radar · NCT00121628
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Last checked: Nov 19, 2026Latest source record: Oct 9, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
184
Actual
Start
Jul 2005
Primary completion
Nov 2006
Study completion Oct 2010
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local therapies.
Conditions
- Thyroid Cancer
Interventions
AMG 706Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (complete response and partial response) as defined by modified RECIST
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.